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Abstract
Whilst heterozygous germline mutations in the ABRAXAS1 gene have been associated with a hereditary predisposition to
breast cancer, their effect on promoting tumourigenesis at the cellular level has not been explored. Here, we demonstrate in
patient-derived cells that the Finnish ABRAXAS1 founder mutation (c.1082G>A, Arg361Gln), even in the heterozygous state
leads to decreased BRCA1 protein levels as well as reduced nuclear localization and foci formation of BRCA1 and CtIP. This
causes disturbances in basal BRCA1-A complex localization, which is reflected by a restraint in error-prone DNA
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double-strand break repair pathway usage, attenuated DNA damage response and deregulated G2-M checkpoint control. The
current study clearly demonstrates how the Finnish ABRAXAS1 founder mutation acts in a dominant-negative manner on
BRCA1 to promote genome destabilization in heterozygous carrier cells.
Graphical Abstract
Introduction
ABRAXAS1 (BRCA1 A complex subunit abraxas 1, a.k.a. ABRA1,
CCDC98 or FAM175A) is a tumour-suppressor gene in the BRCA
pathway that displays mutations or copy number loss in several
human cancers (1). The gene encodes a protein of 409 amino
acids (aa; 47 kDa), containing four recognized key elements: an
Mpr1 and PAD1 N-terminal (MPN)-like domain (aa 11–121), a
coiled-coil region (aa 206–260), a nuclear localization signal (NLS,
aa 358–361) and a pSPxF motif (aa 406–409) (2).
ABRAXAS1 acts as the central scaffold protein of the BRCA1-
A complex, which is comprised of BRCA1, ABRAXAS1, MERIT40,
RAP80, BRCC45 and BRCC36 (2–5). When phosphorylated at
its pSPxF motif, ABRAXAS1 is being bound by the C-terminal
domain of BRCA1 (BRCT) (2–4). The NLS domain is important
for translocation of BRCA1-A complexes into the cell nucleus to
DNA damage sites (6).
Upon histone H2AX phosphorylation at serine 139 (γH2AX),
RNF8 and RNF168 are recruited to the DNA damage sites, which
generates K63 linked poly-ubiquitin (Ub) chains on histones (7).
These are bound by RAP80 via its Ub interacting motif domains
and thus act as docking sites for the BRCA1-A complex (8). It
is suggested that this multiprotein complex regulates the DNA
damage response process by deubiquitinating the K63-linked
poly-Ub chains (5). Consequently, down-regulation of any com-
ponent in the BRCA1-A complex compromises the recruitment
of BRCA1 to the DNA damage sites (2,9–14).
In addition to ABRAXAS1, the BRCA1 BRCT domain also
directly binds some other pSPxF motifs in a phosphorylation-
dependent manner, thus enabling interaction with BACH1
(BRIP1/FANCJ) and CtIP (RBBP8), resulting in the formation of
BRCA1-B and BRCA1-C complexes, respectively (15). All three of
these BRCA1 containing complexes compete for the availability
of the endogenous BRCA1 protein. Disruption of the BRCA1-
A complex by knockdown of RAP80 or ABRAXAS1 propagates
BRCA1-B and BRCA1-C enhanced complex formation (8).
The BRCA1-A complex is also involved in G2-M checkpoint
control, apoptosis and transcription (2,16). In 2012, we reported
a heterozygous germline alteration, c.1082G>A (Arg361Gln), in
the ABRAXAS1 gene in Northern Finnish breast cancer (BC)
families (6). Although hereditary cancer-associatedmutations in
ABRAXAS1 in general appear to be relatively rare, c.1082G>A
is a founder mutation in the Finnish population. According to
the Exome Aggregation Consortium, the same mutation has
also been observed in non-Finnish Europeans and Latinos (17).
The specific alteration (Arg361Gln) resides in the NLS, and was
shown in a model system to impair the localization of the
BRCA1-A complex to the nucleus and ultimately interfering with
the BRCA1-mediated DNA damage response (6). In addition,
the ABRAXAS1 NLS domain is frequently targeted by somatic
missense mutations in several types of cancer (1).
In the current study, we have used peripheral blood samples
and lymphoblastoid cell lines (LCLs) derived from heterozygous
Finnish ABRAXAS1 c.1082G>A (Arg361Gln) pathogenic variant
carriers and ethnically as well as geographically matched
healthy control individuals to study themolecular and biological
mechanisms related to hereditary predisposition to BC. We
demonstrate that in the heterozygous state the Finnish
ABRAXAS1 founder mutation leads to reduced protein levels as
well as nuclear localization of BRCA1. This causes disturbances
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/24/4148/5599814 by O
ikeustiet. kirjasto user on 02 M
arch 2020
4150 Human Molecular Genetics, 2019, Vol. 28, No. 24
in basal BRCA1-A complex localization, which is reflected by
a restraint in error-prone DNA double-strand break (DSB) repair
pathway usage, attenuated DNA damage response and leakiness
of the G2-M checkpoint. Mislocalization of BRCA1 together
with reduced BRCA1 (and BRCA1-A complex) mediated damage
response provide a likely explanation for the cancer phenotypes
observed in heterozygous Finnish ABRAXAS1 mutation carriers.
Results
Unchanged ABRAXAS1 expression level in
heterozygous ABRAXAS1 c.1082G>A carrier cells
The Finnish ABRAXAS1 c.1082G>A founder mutation has been
shown to be associated with increased risk and early onset of
BC and possibly some other malignancies (6). Overexpression
of ABRAXAS1 Arg361Gln was shown to affect BRCA1 foci for-
mation (6), but it was unclear how this mutation affects cells
at physiological levels in a heterozygous state. We therefore
established a set of LCLs of ABRAXAS1 c.1082G>A carriers and
geographically and ethnically matched controls. In quantita-
tive polymerase chain reaction (qPCR) analysis, mutation carrier
LCLs showed comparableABRAXAS1mRNA levels [96.8%±16.8%
(s.d.)] to those of controls (Supplementary Material, Fig. S1A).
RNA-Seq data showed that ABRAXAS1 c.1082G>A transcripts
were present at levels comparable to those of the wild-type (wt)
allele (46.5%±6.7% of totalABRAXAS1 reads including the c.1082
site; Supplementary Material, Table S1). In western blot (WB)
analysis, we observed equal ABRAXAS1 protein expression in
carrier and control cells (Supplementary Material, Fig. S1B and
C), indicating thatmutant ABRAXAS1 is endogenously expressed
at the same level as and shows comparable stability to the wt
protein (6,18).
Mutant ABRAXAS1 protein causes partial BRCA1
mislocalization
Since the observed ABRAXAS1 single nucleotide change resides
in the NLS domain responsible for nuclear localization,we inves-
tigated potential changes in its subcellular localization in our
cohorts by using high content analysis. The automated anal-
ysis strategy used to assess the subcellular localization pat-
tern of different proteins in a large number of cells unbiasedly
is shown in Supplementary Material, Figure S2. As expected,
we observed significantly less ABRAXAS1 localization in the
nucleus of mutation carrier cells (z-scores, carriers: −1.97 ver-
sus controls: 0.00, P =0.0012) (Fig. 1A). As BRCA1 constitutes a
central part of the BRCA1-A complex, we also checked for the
subcellular localization of BRCA1. Similarly to ABRAXAS1, there
was a significantly smaller fraction of BRCA1 in the nucleus of
ABRAXAS1mutation carrier cells (z-scores, carriers:−2.12 versus
controls: 0.00, P =0.0076) (Fig. 1B). To confirm that expression
of mutant ABRAXAS1 is sufficient for the mislocalization of
BRCA1, we transiently transfected MCF7 cells with plasmids
for expression of wt and c.1082G>A ABRAXAS1, respectively.
Indeed, we observed a high correlation of BRCA1 subcellular
misdistribution with that of recombinant mutant ABRAXAS1,
but not with wt ABRAXAS1 (Supplementary Material, Fig. S3A).
These results indicate that in ABRAXAS1 mutation carrier cells
both ABRAXAS1 and BRCA1 proteins are to a significant degree
mislocalized to the cytoplasm.
We next compared their foci formation pattern between
our cohorts by automated high content analysis. In carrier
cells, we observed 13.5% less spontaneous ABRAXAS1 foci, but
this remained under the statistical significance threshold (z-
scores, carriers: −0.57 versus controls: 0.00, P =0.074) (Fig. 1C
and Supplementary Material, Fig. S3B). In parallel, the number of
BRCA1 foci was significantly lower (∼55% less; z-scores, carriers:
−0.96 versus controls: 0.00, P =0.028) in the ABRAXAS1mutation
carrier cells (Fig. 1D and Supplementary Material Fig. S3B).
Furthermore, co-localization between ABRAXAS1 and BRCA1
foci was also significantly reduced in the ABRAXAS1 mutation
carrier cells (co-localizing foci per nuclei, carriers: 0.83 versus
controls: 2.13, P =0.029) (Fig. 1E). Importantly, the percentage of
ABRAXAS1 foci coinciding with BRCA1, but not vice versa, was
affected (Supplementary Material, Fig. S3C and D). The notion
of reduced BRCA1-ABRAXAS1 complex formation in nuclei
was supported by a proximity ligation assay (PLA), where the
significant induction of ABRAXAS1 and BRCA1 interaction was
no longer observed 4 h post irradiation (IR) in the ABRAXAS1
mutation carrier cells (Fig. 1F and G). Taken together, the results
from both the current study using heterozygous mutation
ABRAXAS1 mutation carrier cells and previous one (6) utilizing
a cellular model system stably expressing this mutant allele
support the view that the mutant ABRAXAS1 protein leads to
reduced nuclear BRCA1-A complex localization.
Reduced CtIP recruitment in cells from ABRAXAS1
mutation carriers
CtIP is a nuclease essential for activation of the microhomology-
mediated end joining (MMEJ), single-strand annealing (SSA) and
homologous recombination (HR) pathways (19). When inspect-
ing the subcellular localization of CtIP, we found that similarly
to both ABRAXAS1 and BRCA1, CtIP showed augmented localiza-
tion to the cytoplasm relative to the nucleus in the heterozygous
ABRAXAS1mutation carrier cells (z-scores, carriers:−1.12 versus
controls: 0.00, P =0.021) (Fig. 2A). The cytoplasmic mislocaliza-
tion of CtIP could also be reproduced by transient transfection
of MCF7 cells with a plasmid expressing ABRAXAS1 c.1082G>A,
but not the wt cDNA (SupplementaryMaterial, Fig. S4A). Further-
more, the number of spontaneous CtIP foci was reduced by 35.5%
(z-scores, carriers: −1.17 versus controls: 0.00, P =0.021) in the
mutation carrier cells (Fig. 2B). In WB, no significant change in
CtIP expression between our cohorts was observed, indicating
that CtIPmislocalization and its compromised recruitment is not
due to differences in protein dosage (Supplementary Material,
Fig. S4B,C).
Taken together,ABRAXAS1mutation carriers display reduced
levels of CtIP in the nucleus and thereby reduced recruitment to
spontaneous DNA damage sites. The compromised CtIP recruit-
ment is likely due to impaired recruitment of BRCA1, similarly
to that found by Pathania and coworkers (20) in their study of
BRCA1mut/+ cells.
As S/G2 phase-specific phosphorylation of CtIP at Ser327
by CDKs is necessary for its interaction with BRCA1 and
formation of the BRCA1-C complex (21), we checked for the
levels of CtIPpSer327 in our two cohorts. In WB analysis, no
significant change in CtIPpSer327 levels was observed between
our cohorts (Supplementary Material, Fig. S4D–F). Moreover, PLA
experiments also showed comparable association of BRCA1 and
MRE11 at both untreated state and 4 h post IR in both cohorts
(Supplementary Material, Fig. S4G), indicating no defects in
BRCA1-C complex formation per se.
In respect to BRCA1-B complex formation, BACH1 and TopBP1
protein expression was potentially increased by 64 (P =0.059)
and 71% (P =0.058), respectively, in our ABRAXAS1 mutation
carrier cohort (Supplementary Material, Fig. S5A–D). However,
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Figure 1. Mutant ABRAXAS1 protein affects the localization of BRCA1. Heterozygous ABRAXAS1 c.1082G>A mutation carrier LCLs show reduced relative nuclear
localization of ABRAXAS1 (A) and BRCA1 (B) during unperturbed growth when compared to controls. The ratio between mean nuclear and cytoplasmic ABRAXAS1 and
BRCA1 immunofluorescence signal intensity was determined utilising a high content analysis as described in Supplementary Material, Figure S2. Furthermore, the
mutation carriers show (C) a trend of lower average number of spontaneous ABRAXAS1 foci and (D) a significantly lower spontaneous BRCA1 foci number. In order
to omit any bias derived from the use of specific fluorophores, biological repeats were performed with secondary antibodies conjugated with either AF488 or AF647.
This affected the absolute numbers of foci detected per nuclei by the automated system, but not the relative abundance. Therefore, z-scores rather than foci numbers
were averaged and statistically evaluated. For instance, using AF647 conjugates, we detected on average 4.42 foci per nucleus in ABRAXAS1mutation carriers compared
to 5.25 in controls. Also (E) a significant decrease in the number of co-localization between ABRAXAS1 and BRCA1 foci was observed in the mutation carriers. Lines
in the dot plots (A–E) represent means and statistical significance of differences was evaluated by two-tailed Student’s t-test. Dot plot represent results from (A) six
biological duplicates (BD); >3500 nuclei/sample analysed, (B) three BD; >2500 nuclei/sample, (C) four BD; >250 nuclei/sample and (D and E) > 50 nuclei/sample (single
determination). Shown in (F and G) are the PLA findings for BRCA1 and ABRAXAS1. In (F) the mean values for irradiated controls were defined as 100% (absolute mean
values are 5.2 foci/cell; two independent experiments). Statistically significant differences were calculated using Mann–Whitney U, two-tailed test. In (G) representative
images of wt (BR-1319) and ABRAXAS1 mutant LCLs (BR-1235) are shown.
PLA experiments did not indicate any change in the interaction
between BRCA1 and TopBP1 between our cohorts (Supplemen-
tary Material, Fig. S5E), suggesting that BRCA1-B complex forma-
tion was not affected.
Impairment of BRCA1-A complex affects DNA repair
pathway choice
Several studies have shown that the BRCA1-A complex is crucial
for DSB signalling. In the light of reduced ABRAXAS1, BRCA1
andCtIP foci formation and complex localization to spontaneous
DNA damage sites (Figs 1C–E and 2B and Supplementary Mate-
rial, Fig. S3C and D) in the studied ABRAXAS1 mutation carrier
cells, we set out to assess how this affects DSB repair pathway
usage. We introduced different eGFP-based reporter constructs
for total non-homologous end joining (NHEJ), HR, MMEJ, SSA
and SSA+HR into the LCLs, followed by flow cytometric scoring
of repair proficient eGFP positive cells (22,23). No significant
differences were observed in either NHEJ or HR repair path-
way usage between the two cohorts (Fig. 3A and B). However, in
the ABRAXAS1 mutation carrier cells we observed a significant
decrease in the usage of error prone repair pathways: MMEJ
(relative mean value in carriers: 61%, P =0.001), SSA (relative
mean value in carriers: 86%, P =0.029) and SSA+HR (relative
mean value in carriers: 76%, P =0.004) (Fig. 3C–E). These results
indicate that activation of DSB repair pathways, which utilize
excessive nucleolytic end trimming such as SSA and MMEJ are
suppressed in ABRAXAS1 mutation carrier cells. Importantly,
this is not due to increased population of cells in G1 phase in
carrier cells, when NHEJ is favoured (Supplementary Material,
Fig. S6A, left panel (0 h)).
Detection of single-stranded DNA by RPA and its subsequent
phosphorylation by checkpoint kinases is a common indicator
for end-resection.We observed a trend of reduced foci formation
4 h after IR with 2 Gy IR (P = 0.072) by immunofluorescence
microscopy analysis (Supplementary Material, Fig. S7A). On the
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Figure 2. Heterozygous ABRAXAS1 mutation affects CtIP localization. Heterozygous ABRAXAS1 mutation carriers show (A) reduced relative nuclear localization of
CtIP and (B) significantly less spontaneous CtIP foci during unperturbed growth than controls. Lines in the dot plot represent median, statistical significance of
differences was evaluated by Mann–Whitney U test. Dot plot represent results from (A) two biological duplicates (BD); >1000 nuclei/sample analysed and (B) two
BD; >150 nuclei/sample.
Figure 3. DSB repair pathway usage in heterozygous ABRAXAS1-mutated and wt individuals. Cohort analysis using a GFP reporter assay for the analysis of (A) NHEJ,
(B) HR, (C) MMEJ, (D) SSA and (E) SSA+HR. LCLs from eight ABRAXAS1 c.1082G>A mutation carriers (grey boxes) and seven wt ABRAXAS1 individuals (white boxes)
were transfected with reporter constructs for analysis as described in (20). From each LCL, six biological replicates were analysed in two independent experiments
and normalized to the mean repair frequencies of all wt cell lines measured the same day, which was defined as 100% (average of absolute values corresponding to
100%: NHEJ, 5.3×10−3; HR, 1.8×10−4; MMEJ, 3.3× 10−4; SSA, 2.6×10−3; SSA+HR, 1.8× 10−3). Data are shown in box plots (n =48) including mean value (cross) and
median (line), 95% CI. Statistically significant differences were calculated with SPSS using a general linear mixed model with mutation status as fixed factor and date
of experiment as random factor.
other hand,when studying levels of RPA phosphorylated at Ser33
by flow cytometry before and after treatment with etoposide
(ETO), there was no difference between carriers and controls
in any cell cycle phase (Supplementary Material, Fig. S7B). We
noticed that variation in phospho-RPA levels between differ-
ent LCLs was high. Taken together, our data hint towards a
reduced end resection, but do not support a major defect in end
resection.
Heterozygously mutant ABRAXAS1 cell lines display
only marginally increased origin firing
Previously, we showed that LCLs of heterozygous carriers of the
PALB2 c.1592delT Finnish founder mutation displayed increased
dormant origin firing (24), and replication stress has been gener-
ally recognized as a major driver of genomic instability promot-
ing tumourigenesis (25,26).We therefore studiedDNA replication
in a randomly selected subset of our ABRAXAS1mutation cohort
using the DNA fibre assay. There is no apparent change in the
elongation rate between our cohorts (Fig. 4A). Nevertheless, we
observed a possible increase in the frequency of first pulse
replication origins fired (carriers 17.7% versus controls 11.9%,
P =0.055) in the ABRAXAS1mutation carrier cells (Fig. 4B). Unlike
PALB2 mutation carriers, we did not observe differences in the
level of stalled forks after ETO treatment (Fig. 4C). It was previ-
ously suggested that ABRAXAS1 is not required during replica-
tion as no changes were observed in stalled replication forks in
ABRAXAS1 knockout mouse embryonic fibroblasts (MEFs) (1). In
the current study of heterozygous ABRAXAS1 mutation carrier
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Figure 4. ABRAXAS1 mutation carrier cells display little DNA replication stress phenotype. DNA fibre assay showing changes in stalled forks, replication origin firing
and elongation in four different ABRAXAS1 mutation carriers and four control cell lines. (A) Dot plot showing that there are no significant differences in elongation
rate (kb/min) between our cohorts under normal growth conditions without any toxic treatment. However, (B) mutation carriers showed an increase in the frequency
of first pulse replication origins fired. (C) Dot plot showing that there is no significant difference in the number of stalled forks present after ETO treatment between
our cohorts. Stalled forks present after ETO treatment was normalized to the amount of stalled forks present in untreated conditions. Dot plot represent mean values
± s.e.m. for each cell line. Lines in the dot plot represent means statistical significance of differences was evaluated by two-tailed Student’s t-test. Dot plot represent
results from >200 replication structures total from three independent determinations.
cells, however, the observance of amoderate increase in the first
pulse replication origins fired could be attributed to the limited
availability of BRCA1 as it is needed to support DNA replication
particularly when experiencing stress (27).
When looking at spontaneous chromosomal aberrations,
we did not observe any telomeric associations, complex
chromosomal rearrangements, chromatid/chromosome breaks
and deletions in primary lymphocytes of ABRAXAS1 mutation
carriers (Supplementary Material, Table S2). There was, however,
a possible slight increase in simple chromosomal rearrange-
ments (carriers: 2.9 (0.0–4.0), controls: 0.0 (0.0–2.0), P =0.108) in
the ABRAXAS1 mutation carrier cells (Supplementary Material,
Table S2), but limitations in the availability of study material
precluded conclusive evaluation. Taken together, ABRAXAS1
mutation carrier cells display only a moderate increase in origin
firing replication phenotype, and at best, weak indications
of chromosomal instability. This suggests that the cellular
phenotypes observed in the mutation carrier LCLs are not
primarily driven by DNA replication stress.
Attenuated G2-M checkpoint maintenance in
ABRAXAS1 mutation carrier cells
As BRCA1-A is implicated in the DNA damage response, par-
ticularly G2-M checkpoint control, we next analysed cell cycle
distribution in our cohorts in response to 0.5 μM of the topoiso-
merase II inhibitor ETO. No significant change in cell cycle dis-
tribution was observed between our cohorts during the first 7 h
of treatment (Supplementary Material, Fig. S6A and B). However,
there was a significantly higher M/G2 ratio in the ABRAXAS1
mutation carriers at 24 h post ETO treatment, (relative M-G2
ratio in carriers—151%, P =0.031), which is indicative of G2-M
checkpoint leakage (Fig. 5A). When following the response to
ETO over time, it becomes apparent that both cohorts display
a progressive G2 arrest, but mutation carrier cells to a lesser
extent (Supplementary Material, Fig. S6B). This is in line with
the observance of G2-M checkpoint failure after γ -IR in cells
overexpressing mutant ABRAXAS1 protein (6). Thus, heterozy-
gous ABRAXAS1 mutation carrier cells could activate the G2-M
checkpoint proficiently, but maintained it less efficiently than
the controls.
Both ataxia telangiectasia mutated (ATM) and CHK2 play a
key role in activating and maintaining the G2-M checkpoint.
We therefore characterized the response of our cohorts to ETO
treatment in terms of changes in ATM and CHK2 levels and
phosphorylation. No significant change in the stabilisation and
phosphorylation of ATM and CHK2 was observed between our
cohorts during the first 7 h of treatment (Supplementary Mate-
rial, Fig. S6C). However, at 24 h post ETO, we found significantly
reduced ATM (79%, P =0.019) and CHK2 protein (72%, P =0.031)
in ABRAXAS1mutation carrier LCLs (Fig. 5B–E). Despite the pres-
ence of ATM damage response among mutation carriers, this
reduced ATM and CHK2 levels at 24 h may explain the observed
attenuation of G2-M checkpoint maintenance (28,29).
DNA damage persistence in heterozygous ABRAXAS1
mutation carrier cells
In order to address how the observed molecular phenotypes in
our ABRAXAS1 LCL cohort influence the overall levels and pro-
gression of DNA damage and damage signalling,we investigated
γH2AX as an early global indicator of DSBs. At untreated state,
no significant differences were seen in the spontaneous γH2AX
foci numbers between our cohorts (Supplementary Material, Fig.
S8A). Instead, a moderate, nevertheless significant decrease in
γH2AX foci intensity by ∼15.5% was observed in the ABRAXAS1
mutation carrier cells (z-scores, carriers: −2.44 versus controls:
0.00, P =0.0024) (Fig. 6A). To further elaborate on this observation,
we used a flow cytometric approach to quantify global γH2AX
levels. Indeed, the ABRAXAS1mutation carrier cells showed also
a modest, but significant decrease in γH2AX intensity (relative
mean intensity in carriers: 90.4%,P =0.031) (Fig. 6B).When apply-
ing cell cycle specific analysis,we found a significant decrease in
γH2AX intensity only in the G1 (relativemean intensity, carriers:
89.8%, P =0.021) and S (relative mean intensity in carriers: 90.1%,
P =0.042) (Fig. 6C) populations.
We next looked at the levels and persistence of DNA damage
induced by ETO. There was no difference between the cohorts in
foci numbers of 53BP1, γH2AX and RAD51 in untreated condition
or up to 7 h of treatment (Supplementary Material, Fig. S8).
In contrast, at 24 h post ETO we found significantly increased
numbers of 53BP1 (∼71% more; z-scores, carriers: 3.48 versus
controls: 0.00, P =0.011), γH2AX (∼31% more; z-scores, carriers:
1.66 versus controls: 0.00, P =0.030) and RAD51 foci (∼64% more;
z-scores, carriers: 2.14 versus controls: 0.00, P =0.010) in the
mutation carrier cells, indicating the presence of more residual
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Figure 5. ABRAXAS1mutation carriers showmild ATM checkpointmaintenance defect. (A)ABRAXAS1mutation carriers show significantlymoremitotic cells relative to
G2 cells in presence of 0.5 μM ETO for 24 hwhen compared to controls. G2-M checkpoint was analysed by flow cytometry, themeanM/G2 ratio of carriers was set to 100%
for the controls in individual experiments. (B and D) Representative immunoblot showing ATM (B; 350 kDa) and CHK2 (D; 61 kDa) protein levels after 24 h presence
of 5 μM ETO. Protein levels were normalized against β-tubulin (55 kDa) and Cyclophilin B (21 kDa), respectively. Significant down-regulation of ATM (C) and CHK2
(E) was observed in ABRAXAS1 mutation carriers. Lines in the dot plot represent means; statistical significance of differences was evaluated by two-tailed Student’s
t-test. Dot plot represent results from (A) two biological duplicates; >20 000 events/sample analysed and (C and E) two technical repeats.
DNA damage (Fig. 7A–C). These results indicate that heterozy-
gous ABRAXAS1 mutation carrier cells initiate DNA repair after
ETO treatmentwith normal kinetics, but are left withmore resid-
ual DNA damage at 24 h. This was not accompanied by a higher
sensitivity of the carrier cells against DNA damage induced by
ETO or MMC, as IC50 values determined by an alamarBlue assay
for these agents did not differ significantly between carrier and
control cell cohorts (Supplementary Material, Fig. S9). Previously,
homozygous ABRAXAS1 knockout MEFs have shown high levels
of unrepaired DNA damage after IR (1). Here we demonstrate a
similar, albeit weaker phenotype in the heterozygous ABRAXAS1
mutation carrier cells.
We now analysed the response of ABRAXAS1, BRCA1 and CtIP
after ETO treatment. Surprisingly, in contrast to the untreated
state (Figs 1 and 2), no difference between the cohorts was
observed in the subnuclear localization of ABRAXAS1, BRCA1
and CtIP after 7 h and 24 h of ETO treatment (Supplementary
Material, Fig. S10A–F). All of these proteins were predominantly
nuclear, indicating their engagement in repair of ETO-induced
DNA damage. Similarly, all three proteins formed comparable
numbers of foci in both cohorts at 7 h ETO (Supplementary
Material, Fig. S10G–I). However, at 24 h of ETO, there was a
potential increase in the number of foci formed by BRCA1 (∼80%
more; z-scores, carriers: 2.18 versus controls: 0.00, P =0.068) and
CtIP (∼27% more; z-scores, carriers: 0.86 versus controls: 0.00,
P =0.068), but not by ABRAXAS1 in the mutation carrier cells
(Fig. 7D–F). This is in line with the augmented level of RAD51
foci in the mutation carrier cells (Fig. 7C). It was previously
shown that BRCA1 is required for the recruitment of CtIP and
RAD51 to the sites of DNA damage (20). Thus, all of the results
are consistent with a delayed completion of DSB repair in the
heterozygous ABRAXAS1 mutation carrier cells.
Reduced caspase activation in heterozygous ABRAXAS1
mutation carrier cells
Recently, a pro-apoptotic role has been reported for the BRCA1-
A complex (16). We therefore explored apoptosis activation by
measuring flow cytometric caspase activation of our cohorts at
both untreated state and after 24 h in the presence of 0.5 μM
ETO. In untreated ABRAXAS1 mutation carrier cells, there were
significantly less caspase positive cells (9.4% and 13.1% of cells
with active caspase in carriers versus control, respectively,
P =0.0052; Fig. 8A). However, at 24 h of ETO treatment, we
no longer observed any differences in the number of caspase
positive cells between our cohorts (Fig. 8B).
Discussion
Since the identification of BRCA1 and BRCA2 as high-risk BC
susceptibility genes, it has become apparent that pathogenic
variants in multiple genes of the BRCA damage response path-
way increase the hereditary risk of BC and other malignancies.
Functional characterisation of BC promoting mutations has
traditionally been based on analysis of tumour-derived cell lines,
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Figure 6. Heterozygous ABRAXAS1 mutation affects γH2AX signalling.(A) ABRAXAS1 mutation carriers show significantly lower γH2AX foci intensity than controls.
Dots represent mean spontaneous γH2AX foci intensity of individual LCLs during undisturbed growth. Averages of z-scores were used to accommodate for variation
in absolute intensities between biological replicates. (B) Significantly reduced γH2AX intensity in the whole cell population of ABRAXAS1mutation carriers. (C) γH2AX
intensity is significantly lower only in G1 and S but not in the G2-M population of the mutation carriers. Lines in the dot plot represent means; statistical significance
of differences was evaluated by two-tailed Student’s t-test. Dot plot represent results from (A) three biological duplicates (BD); >50 nuclei/sample analysed, (B and C)
three BD; >30000 events/sample.
permanently or transiently induced mutant allele overexpres-
sion, cellular knockdown or knockout approaches or mouse
models. Only few studies have taken on the challenge of
analysing the molecular and biological effects of mutations
at the heterozygous state, using patient-derived material or
models. This may be due to the heterogeneity or limited
availability of human samples and the less pronounced or
recessive phenotypes found in the heterozygous state. However,
increasing evidence points to subtle haplo-insufficiency (or
possibly mild dominant-negative) phenotypes of BC suscepti-
bility gene germline mutations (20,24,30) that likely represent
important disease drivers early in tumourigenesis, alone or in
combination with other acquired mutations (31–33).
In the present study, we have comprehensively character-
ized the molecular and functional consequences of the het-
erozygous Finnish ABRAXAS1 c.1082G>A founder mutation in
a carrier-derived LCL cohort. Germline mutations in ABRAXAS1
have been associatedwith BC aswell as certain types of rare can-
cers (6,34–36). The average age of disease onset for the Finnish
ABRAXAS1 c.1082G>A mutation carriers is 51 years (variation:
35 to 60 years; this cohort), compared to 46 years in Finnish
BRCA1 (variation: 32 to 57 years), 48 years in BRCA2 (variation:
45 to 67 years) and 53 years in PALB2 carriers (variation: 39 to
73 years) (37,38).
Our data support a model where attenuation of BRCA1-A
function and reduced BRCA1 availability give rise to an aberrant
DNA damage response that may be underlying the increased
cancer susceptibility (Fig. 9).
From our results, it is apparent that the BRCA1 mislocaliza-
tion is due to a dominant-negative effect of mutant ABRAXAS1
as shown in both LCLs and MCF7 cells. BRCA1 mislocalization
in the ABRAXAS1 mutation carrier cells could also be directly
responsible for the mislocalization of CtIP and subsequently
MMEJ and SSA suppression in the carrier cells, likely due to
reduced nuclear BRCA1-A complex formation (39). Alternatively,
the overall balance between BRCA1-A, -B and -C complexes may
be disturbed. Furthermore, our results suggest that themislocal-
ization and reduced levels of BRCA1 is the reason for attenuated
G2-M checkpoint maintenance, higher DNA damage persistence
and reduced caspase activation (Fig. 9).
It is noteworthy that most of the phenotypic changes
observed in the ABRAXAS1 mutation carrier cells are mild in
nature, as there are only moderate changes in ABRAXAS/BRCA1
expression and redistribution. It appears that only a subset of
BRCA1 functions, directly or indirectly linked to the BRCA1-
A complex have been significantly affected in the ABRAXAS1
mutation carriers. The changes observed in spontaneous forma-
tion of ABRAXAS1, BRCA1 and CtIP foci as well as persistence of
DNA damage after ETO are likely due to attenuated DSB damage
response signalling aswell as reduced initiation of resection (40).
Beside the occurrence of specific ABRAXAS1 germline muta-
tions affecting the NLS domain, the NLS of ABRAXAS1 has been
identified as a mutational ‘hot spot’ in several types of tumours
(1), suggesting that also somatic missense mutations disrupting
the NLS are biologically relevant andmay thus represent a driver
of sporadic cancers. Furthermore, the observed mutational ‘hot
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Figure 7. ABRAXAS1 mutation carriers show attenuated DNA damage repair. Foci analysis for 53BP1 (A), γH2AX (B), RAD51 (C), ABRAXAS1 (D), BRCA1 (E) and CtIP (F)
induced after 24 h presence of 0.5 μM ETO. Significantly more 53BP1, γH2AX and RAD51 foci along with comparable ABRAXAS1 foci number and a considerable increase
in BRCA1 and CtIP foci was observed in the heterozygous ABRAXAS1 mutation carriers. Lines in the dot plot represent means; statistical significance of differences
was evaluated by two-tailed Student’s t-test. Dot plot represent results from (A and B) three biological duplicates (BD); >100 nuclei/sample analysed, (C) six BD; >225
nuclei/sample, (D) six BD; >200 nuclei/sample, (E) two BD; >50 nuclei/sample and (F) two BD; >100 nuclei/sample.
Figure 8. ABRAXAS1 mutation carriers show compromised apoptosis. (A) ABRAXAS1 mutation carriers show a significant decrease in caspase activity during
unperturbed growth when compared to controls. (B) There was no difference in caspase activity at 24 h following 0.5 μM ETO addition between the cohorts. The
fraction of caspase positive cells was determined by flow cytometry after incubation with a fluorescent caspase substrate. Dot plot represent results from two biological
duplicates; >60000 events/sample analysed.
spot’ may also explain the observance of the same ABRAXAS1
germline mutation in the NLS domain in different populations
not sharing a common geographic and ethnical origin. In addi-
tion to BRCA1 and ABRAXAS1, pathogenic variants in genes for
other members of the BRCA1-A complex are also implicated
in BC (41–43). Thus, as observed for ABRAXAS1 in the current
study, we expect to see similar phenotypic changes in cells
heterozygous for mutations in genes coding for other BRCA1-
A subunits. The phenotype described here not only provides
a mechanistic insight on how compromised BRCA1-A function
may drive early stage tumourigenesis, but also emphasizes that
complex combinations of rather small changes in different key
cellular pathways, such as DNA damage response, DSB repair,
DNA replication and cell cycle checkpoint maintenance, may be
collectively required to promote tumourigenesis.
Material and Methods
Study subjects
Altogether, eight individuals heterozygous for the ABRAXAS1
c.1082G>A founder mutation were analysed in this study. Of
these, five individuals had been diagnosed with BC, one with
lymphoma and two were disease-free siblings of one bc patient.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/24/4148/5599814 by O
ikeustiet. kirjasto user on 02 M
arch 2020
Human Molecular Genetics, 2019, Vol. 28, No. 24 4157
Figure 9. Proposed model for how the heterozygous Finnish ABRAXAS1 c.1082G>A mutation may drive early stage tumourigenesis in carrier individuals. Due to the
mutation in the NLS domain, ABRAXAS1 is mislocalized into the cytoplasm that results in reduced ABRAXAS1 nuclear foci formation. Further, a prominent dominant-
negative feature of mutant ABRAXAS1 is reduced BRCA1 nuclear foci formation by facilitating BRCA1 mislocalization into the cytoplasm. Reduced BRCA1 localization
and foci formation in the carrier cells results in attenuated BRCA1 signalling, altered DSB repair pathway choice, deregulated G2-M checkpoint maintenance and
decreased apoptosis. Collectively, changes in the above mentioned pathways likely represent drivers of early stage tumourigenesis in the mutation carriers.
The samples of the bc patients were collected at least 3 years
after the initial cancer diagnosis. Seven healthy non-carrier indi-
viduals served as controls, one ofwhich is a healthy familymem-
ber of a patient. For chromosomal analysis, control samples used
in a previous study of ours (24) was used again in this study. All
controls originated from the same geographical region and had
the same ethnical background as themutation carriers, andwere
cancer-free at the time of donation. There was no follow-up on
the health status of the controls. Informed consent to participate
in the study has been obtained from each individual, and the
studies have been approved by the Ethical Board of the Northern
Ostrobothnia Health Care District and Ethics Committee of the
Helsinki University Hospital. Details of the study and control
cohort are presented in Supplementary Material, Table S3.
Cell culture
In order to generate LCLs, Epstein-Barr virus was used to immor-
talize B-lymphocytes obtained from fresh peripheral blood
samples of the participating individuals. LCLs were cultured
in RPMI 1640 medium (Gibco/Invitrogen, Carlsbad, CA, U.S.A.)
supplemented with 20% fetal bovine serum (Gibco, Invitrogen),
1% L-glutamine (Gibco, Invitrogen) and 10μg/ml gentamycin
(B. Braun Melsungen, Germany). MCF7 BC cell line (ATCC HTB-
22TM, Manassas, Virginia, USA) was cultured in Dulbecco’s
modified Eagle Medium, high glucose, with sodium pyruvate
(Gibco, Invitrogen) supplemented with 10% fetal bovine serum,
100 IU/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich
Steinheim, Germany). All cells were maintained at 37◦C in a
5% CO2 atmosphere. All cell lines were tested yearly and were
negative for mycoplasma contamination.
Plasmids and transfection
Wt and c.1082G>A mutant ABRAXAS1 carrying an N-terminal
HA/FLAG-tag were cloned from pOZ-N-ABRAXAS1 vectors into
pcDNA3.1/Hygro(−) backbone. MCF7 cells were transiently
transfected with wt ABRAXAS1, ABRAXAS1 mutant or empty
pcDNA3.1/Hygro(−) vector using Cell Line Nucleofector kit V
(Lonza) according to the manufacturer’s instructions. Nucleo-
fector program E-014 was used for higher cell viability.
WB analysis
Cell lines treated with either 5μM ETO (Etopofos, Bristol–Myer
Squibb and/or ETO, Pfizer, Sigma-Aldrich) or 2mM hydroxyurea
(Sigma-Aldrich), were cultured up to 24 h in the presence of
the agent. Samples were then collected at different time points
(0, 0.5, 1, 2, 3, 5, 7 and 24 h). Following washing, cells were
lysed using NETN-300 buffer (20mM Tris base (pH 7.5), 300mM
NaCl, 1mM EDTA, 0.5% NP-40, 1× complete mini EDTA pro-
tease inhibitor (Roche Diagnostics Mannheim, Germany) and
1× phosphatase inhibitor (Calbiochem Darmstadt, Germany, set
V). Cell lysate was then separated using SDS-PAGE (7.5% or 4–
15% Mini-PROTEAN TGX precast gels, Bio-Rad Helsinki, Finland)
and blotted on to polyvinylidene fluoride (PDVF) membranes.
Membranes were blocked with 1% BSA and 1% non-fat dry milk
in 1× TBST (50 mm Tris, pH 7.5, 150 mm NaCl, 0.05% Tween 20).
Antibody incubations were performed in 1× TBST containing
0.2% BSA and 0.2% non-fat dry milk. The antibodies used in
this study are listed in Supplementary Material, Tables S4 and
S5. Blots were developed as per the manufacturer’s instruc-
tions using either SuperSignalTM West Pico Chemiluminescent
Substrate or SuperSignalTM West Femto Maximum Sensitivity
Substrate (both Thermo Fisher Scientific). Chemiluminescence
was detected using Fujifilm LAS-3000 imaging system. Densito-
metry values were calculated using ImageQuant TL software (GE
Healthcare Helsinki, Finland).
Flow cytometric analysis
Unexposed and 0.5 μM ETO treated cell lines were cultured for
24 h and samples were collected at different time points (0.25,
1, 7 and 24 h). Cells were stained with thymidine analogue 5-
ethynyl-2′-deoxyuridine (EdU) to measure DNA synthesis and
analyse cell cycle distribution as described by the manufacturer
of Click-iT® EdU Alexa Fluor® (AF) 647 Flow Cytometry Assay Kit
(Thermo Fisher Scientific, Vantaa, Finland). Cells were fixedwith
4% PFA and permeabilized using 0.25% Triton X-100. Blocking
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was done with 5% donkey serum. Antibody incubations were
performed in TBP buffer (triton X-100 and BSA in PBS) buffer
(0.2% Triton X-100 and 1% BSA in PBS). All measurements were
performed with LSRFortessa (BD Biosciences Vantaa, Finland)
flow cytometer. FlowJo software was used for quantification
and the gating strategy used for the analysis is available upon
request.
Immunofluorescence and high content analysis
Immunofluorescence was used to automatically (1) analyse foci
number and its characteristics (of γH2AX, 53BP1, ABRAXAS1,
BRCA1, CtIP, RAD51) in the AKLIDES NUK high content analy-
sis system (Medipan Dahlewitz, Germany), and (2) characterize
localization patterns of ABRAXAS1, CtIP and BRCA1 between
nucleus and cytoplasm using the Operetta high content imaging
system (PerkinElmer). For both purposes, untreated cells and
cell lines grown in the presence of 0.5μM ETO for up to 24 h
were used. Samples were collected at 0, 3, 7 and 24 h. Following
washing, LCLs were pipetted on to the slides coated with Teflon
and silane (TEKDON Myakka City, Florida, U.S.A.) and MCF7 into
black CellCarrier 96-well plates (PerkinElmer Turku, Finland).
Cells were fixed with 2% or 4% PFA and permeabilized using
0.2% Triton X-100. Blocking was done using 5% donkey serum.
Antibody incubations were performed either in 1% BSA or in 5%
donkey serum—0.3 m glycine—0.05% tween 20. Functionality of
the staining procedures were controlled by fluorescence micro-
scropic inspection before subjecting the sample to automated
microscopy.
More details on the organization and functioning of both
hardware and software component of the automated AKLIDES
NUK is explained elsewhere (44,45), exemplary images and the
analysis pipeline is presented in Supplementary Material, Figure
S3B. In the Operetta high content imaging system, images were
acquired and analysed using Harmony PhenoLOGIC 3.5.2 and
Columbus 2.5 software, respectively. An exemplary image and
the analysis sequence used to find the localization pattern is
explained in Supplementary Material, Figure S2 and the analysis
script (.aas file) is available upon request.
For both foci and protein localization analysis, different sec-
ondary antibody conjugates for the same primary antibody were
employed in individual experiments to improve robustness of
the analysis. This lead to variation of the absolute values, but
not the relative ones, between biological replicates. Therefore,
Z-scores were used to report the findings in these cases. The
standard formula [z = (x—μ)/σ ; where x represents the individual
experimental value, μ and σ the average and standard deviation
of the respective experiment and z the corresponding z-score]
was used to transform the results of individual experiments into
z-scores.
DNA fibre spreads
Exponential growing cells were pulse labelled with 25μM
CldU (Sigma) followed by 250μM IdU (Sigma) for the indicated
times. For fibre analysis, after damage induction CldU and
IdU media was given for indicated time periods and 10μM
ETO were performed during the last 30min of the CldU pulse.
Labelled cells were harvested and DNA fibre spreads prepared
onmicroscope glass slides by addition of 200mmTris-HCl pH 7.4,
50mm EDTA, 0.5% SDS (46). Acid-treated fibre spreads were
stained with monoclonal rat anti-BrdU followed by monoclonal
mouse anti-BrdU. Fibres were examined using fluorescence
microscope Axioplan 2 (Zeiss, Germany). CldU and IdU tracks
were measured using ImageJ and micrometre values were
converted into kilobases (47). At least 200 replication forks were
analysed. Different classes of tracks were classified; red–green
(ongoing replication), red (stalled or terminated forks), green
(second pulse origin) and red-green-green-red (first pulse origin).
Frequencies were calculated using ImageJ software.
Caspase activation assay
Untreated and cell lines treated with 0.5μM ETO were cultured
for 24 h and samples were collected. Further, caspase activation
assay was performed using the 660 Polycaspase Assay kit
(ImmunoChemistry Technologies, Bloomington, MN, U.S.A.)
according to the manufacturer’s instruction. All measurements
were done in LSRFortessa (BD Biosciences) flow cytometer.
FlowJo software was used for quantification and the gating
strategy used for the analysis is available upon request.
Repair pathway analysis
DNA DSB repair was analysed by use of our EGFP-based test
system, as described earlier (23,48). In brief, different DNA
mixtures, containing expression plasmid for the endonuclease
I-SceI (pCMV-I-SceI) together with one of the DSB repair
substrates (EJ5SceGFP, EJ-EGFP, 5′EGFP/HR-EGFP, HR-EGFP/3′EGFP,
HR-EGFP/5′EGFP) and pBS filler plasmid (pBlueScriptII) or wt
EGFP expression plasmid (for determination of transfection
efficiencies) were introduced by use of a Gene Pulser with
Pulse Controller from Bio-Rad (München, Germany) at 220 V
and 1050 μF. Subsequently, the cells were recultivated for 48 h
and harvested for flow cytometric analysis using FACSCalibur
(Becton-Dickinson, Heidelberg, Germany). Recombination fre-
quencies were measured by quantification of green fluorescent
cells containing reconstituted EGFP within the life cell-
population (SSC/FSC gate) and were individually corrected for
transfection efficiencies determined in split samples each.
Laser excitation was effected at 488-nm and green fluorescent
cells were detected in the FL1/FL2 channel. The recombination
frequency was calculated by green fluorescent cells per life cell
count divided by the transfection efficiency per life cell count.
Proximity ligation assay
LCLs were exposed to 2 Gy of ionizing radiation (Cs-137, GSR
D1, Gamma-Service Medical GmbH, Leipzig, Germany) and har-
vested after 4 h. After cytospinning (Cytospin3 Centrifuge, Shan-
don, Bohemia, NY, USA) at 28×g for 5 min on slides covered
by poly-L-Lysine (Sigma-Aldrich), cells were fixed immediately
with 3.7% formaldehyde followed by permeabilization with 0.5%
TritionX-100, washing and blocking steps with 5% goat serum
(Invitrogen, Karlsruhe, Germany) in PBS. Then cells were double-
stained with the primary antibodies anti-ABRAXAS1 (Abcam,
Cambridge, U.K. ab139191) and anti-BRCA1 (Calbiochem, OP92).
PLA-stain was then performed using Duolink® in Situ Orange
Starter Kit Mouse/Rabbit (Sigma, DUO92102). Glass slides were
stained with Duolink® In Situ PLA® Probe Anti-Rabbit PLUS
(Sigma, DUO92002) and Duolink® In Situ PLA® Probe Anti-Mouse
MINUS (Sigma,DUO92004) for 1 h at 37◦C.Afterwashing the sam-
pleswere incubatedwith the ligation–ligase reaction solution for
30 min at 37◦C to hybridize oligonucleotides tagged on probes.
After two short washing steps, the glass slides were incubated
with the amplification–polymerase reaction solution for 100min
at 37◦C to amplify hybridized oligonucleotides and fluorescently
label the amplification products. Then, glass slides were cov-
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ered with coverslips using Duolink® In Situ Mounting Medium
with DAPI (Sigma, DUO82040). Imaging was performed using
Keyence BZ-9000 microscope (Keyence Neu-Isenburg, Germany).
Automated quantification of PLA-foci was carried out with BZ-II
Analyser software.
Chromosomal analysis
Chromosomal analysis of four heterozygousABRAXAS1 c.1082G>A
carriers (one healthy carrier, three carriers diagnosed with BC)
and nine controls was carried out on metaphases obtained
from regular short-term 3-day cultures of peripheral blood T-
lymphocytes. The blood samples of the studied BC patients
(n =3) were collected 4–18 years after the initial cancer diagnosis.
A minimum of 50 Giemsa-banded metaphases for each sample
were evaluated as mentioned (24).
Statistical analysis
Statistical differences for normally and non-normally dis-
tributed samples were determined using independent samples
student’s t-test and Mann–Whitney U-test, respectively. Mean
values are reported for normally distributed samples; in
case of non-normally distributed samples, median values are
reported. Correlation analysis was done using Spearman’s rank
correlation coefficient and rho scores were reported.All P-values
were two-sided and statistical evaluations were done with IBM
SPSS Statistics (version 20.0).
The statistical significances of PLA foci analyses were deter-
mined by the GraphPad Prism 5.04 software (GraphPad, San
Diego, CA, USA) using non-parametric Mann–Whitney test for
unpaired samples. Cohort analyses of DSB repair pathway usage
were performed using IBM SPSS Statistics Software package
version 21. DSB repair pathway usage was analysed using a
general linear mixed model with mutation as fixed factor and
date of experiment as random factor.
Supplementary Material
Supplementary Material is available at HMG online.
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